Acute Myeloid Leukemia
The trial was not designed to establish definitive relapse-prevention efficacy in AML or MDS. All relapses in the study remained CD33-positive, suggesting relapse was not driven by CD33 antigen loss. Relapse after transplant remains common…
1 sources - 6 claims
The trial was not designed to establish definitive relapse-prevention efficacy in AML or MDS. All relapses in the study remained CD33-positive, suggesting relapse was not driven by CD33 antigen loss. Relapse after transplant remains common in high-risk AML, especially with adverse genetics, measurable residual disease, or secondary AML. Allogeneic hematopoietic cell transplantation is standard care for AML patients unlikely to be cured with chemotherapy alone.